FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used in treatment of cancer. Methods of the invention include administration of a combination of antibody GA101 and 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide (GDC-0199).
EFFECT: use of inventions allows to increase effectiveness of treatment.
22 cl, 5 dwg, 4 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY BASED ON CD20 ANTIBODY COMBINED WITH BCL-2 INHIBITOR AND MDM2 INHIBITOR | 2016 |
|
RU2727196C2 |
| COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR | 2011 |
|
RU2585489C2 |
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| COMBINED THERAPY BY AFUCOSYLATED ANTIBODY FOR CD20 WITH ANTIBODY FOR VEGF | 2011 |
|
RU2615459C2 |
| EFFICACY OF CONJUGATES OF ANTI-TROP-2 ANTIBODY WITH DRUG SN-38 FOR THERAPY OF RECURRENT/REFRACTORY TO INHIBITORS OF TUMOR CONTROL POINT | 2017 |
|
RU2725292C2 |
| TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER CHARACTERIZED BY Trop-2 EXPRESSION USING SATSITUZUMAB GOVITECAN AND Rad51 INHIBITOR | 2018 |
|
RU2758234C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| TREATMENT APPROACH DESIGNED TO TREAT WITH A COMBINATION OF ANTI-CD19 ANTIBODY AND VENETOCLAX | 2018 |
|
RU2802812C2 |
| COMBINED THERAPY BASED ON CD20 ANTIBODY AND BTK INHIBITOR | 2014 |
|
RU2727650C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
